Company profile: SkinBioTherapeutics
1.1 - Company Overview
Company description
- Provider of probiotic bacteria lysate-based skin technologies and products, including the SkinBiotix platform to improve skin barrier integrity, repair and reduce bacterial load; AxisBiotix-Ps probiotic supplement for psoriasis; cosmetic skincare for sensitive skin and anti-aging; food supplements for eczema, psoriasis and acne; medical skin care and infection control solutions for hospital and domestic settings.
Products and services
- SkinBiotix technology platform: Proprietary lysate-based system from probiotic bacteria that improves skin barrier integrity in models, protects against infection, enhances skin repair and healing, and reduces bacterial load
- Cosmetic skincare applications: Probiotic lysate-driven products leveraging SkinBiotix to manage sensitive skin with improved barrier integrity, provide anti-aging benefits, and support skin healing and protection against infection
- AxisBiotix-Ps: Probiotic-formulated food supplement developed to manage symptoms associated with psoriasis, targeting psoriasis-related skin issues through probiotic composition suited for symptom control
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SkinBioTherapeutics
Cellular Highways
HQ: United Kingdom
Website
- Description: Provider of microfluidic cell sorting solutions for research and clinical applications, including Highway1, a fluorescence-based sterile GMP benchtop sorter with Windows host PC and single-use cartridges; mAIvis automated imaging software; VACS thermal vapour bubble vortex deflection; GMP cell sorting systems, sterile GMP cartridges, and pilot-scale manufacturing and scaling services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellular Highways company profile →
Harbour Antibodies
HQ: United States
Website
- Description: Provider of transgenic mouse technology for engineering mice to produce high affinity human antibodies. Established in 2006, leveraging technology developed in the laboratory of Professor Frank Grosveld at Erasmus MC (Rotterdam, the Netherlands). The company has developed two types of human immunoglobulin gene transgenic mice.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Harbour Antibodies company profile →
Hemanext
HQ: United States
Website
- Description: Provider of blood processing, storage, and transfusion solutions. Offers Hemanext ONE, a blood container set for processing and storing red blood cells under reduced oxygen and carbon dioxide conditions to improve quality and extend shelf-life.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hemanext company profile →
Dow Pharmaceutical Sciences
HQ: United States
Website
- Description: Provider of topical drug product development services for pharmaceutical and biotechnology clients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dow Pharmaceutical Sciences company profile →
ActivX Biosciences
HQ: United States
Website
- Description: Provider of biopharmaceutical discovery and development of highly selective, best-in-class small molecule drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ActivX Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SkinBioTherapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SkinBioTherapeutics
2.2 - Growth funds investing in similar companies to SkinBioTherapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SkinBioTherapeutics
4.2 - Public trading comparable groups for SkinBioTherapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →